Full-year 2026 GAAP operating expense guidance was raised to $1.7 billion - $1.8 billion, primarily driven by accelerated ...

BeOne Medicines AG ( NASDAQ:ONC ) defied analyst predictions to release its first-quarter results, which were ahead ...

An experimental drug from Revolution Medicines that nearly ​doubled survival time for patients with advanced pancreas cancer ...

Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; ...

The war in the Middle East has “aggravated the situation”, it is “not the sole reason for the shortage”, said Pharmacy ...

The data published in NEJM reflect outcomes in the PDAC cohort from the RMC-6236-001 trial (NCT05379985), an open-label, multicenter Phase 1/2 trial evaluating daraxonrasib monotherapy in patients ...

1. The non-GAAP adjustments are based on best available information at this time related to non-cash items similar to those reported in our actual Non-GAAP results.

The company has multiple drugs in its pipeline that could generate billions in revenue.

Delhi police cracks fake drug racket, arrests four persons and seizes medicines worth Rs. 6 crore: Our Bureau, New Delhi Friday, May 8, 2026, 15:20 Hrs [IST] The Delhi police has ...

Revolution Medicines received a "safe to proceed" letter from the Food and Drug Administration, allowing the pharmaceutical company to launch an expanded-access treatment protocol for its ...

Patients in Cyprus wait on average more than 500 days to access new medicines, one of the longest delays in Europe, as officials warn the EU is falling behind global competitors in pharmaceutical ...

Good day, and thank you for standing by. Welcome to the Revolution Medicines Q1 2026 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now ...